Polynucleotide derived from novel hepatitis c virus strain and use thereof
AssigneesPhoenixbio Co., Ltd., Tokyo Metropolitan Institute of Medical Science
InventorsMichinori KOHARA, Masaaki ARAI, Chise MUKAIDANI
Life of this patent
Estimating the term…
Abstract
A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.
Claims10
A method of screening or evaluating a drug candidate substance which inhibits replication or protein translation of HCV, comprising
- administering or adding said drug candidate substance to a non-human mammal or an isolated cell to which a recombinant polynucleotide has been introduced and which produces a recombinant HCV and
- evaluating replication capacity of HCV or capacity of translation of HCV protein, wherein said recombinant polynucleotide encodes an amino acid sequence having at least 99% identity to the entire sequence set forth in SEQ ID NO:2 and said amino acid sequence comprises a glutamic acid to glycine substitution at position 1202 of SEQ ID NO:2.
A method of screening or evaluating a drug candidate substance which inhibits replication or protein translation of HCV, comprising
- administering or adding said drug candidate substance to a non-human mammal or an isolated cell to which a recombinant polynucleotide has been introduced and which produces a recombinant HCV and
- evaluating replication capacity of HCV or capacity of translation of HCV protein, wherein said recombinant polynucleotide encodes an amino acid sequence having at least 98% identity to the entire sequence set forth in SEQ ID NO:2 and said amino acid sequence comprises a glutamic acid to glycine substitution at position 1202, a glutamic acid to valine substitution at position 1056, and a alanine to threonine substitution at position 2199 of SEQ ID NO:2.
Dependencies are inferred from the claim text.